This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised
by Zacks Equity Research
Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up
by Zacks Equity Research
Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.
NextGen Healthcare (NXGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal first-quarter earnings reflect strong segmental performance.
Cerner (CERN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cerner's (CERN) second-quarter results benefit from gains across six of its business units.
Company News for Jul 28, 2021
by Zacks Equity Research
Companies In The News Are: RGEN, SIRI, BSX, FISV.
Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up
by Zacks Equity Research
Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 8.11% and 4.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Boston Scientific (BSX) Ahead of Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings
by Zacks Equity Research
Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Avanos (AVNS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni
Top Analyst Reports for Oracle, Lockheed Martin & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Lockheed Martin (LMT), and Boston Scientific (BSX).
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake
by Zacks Equity Research
Boston Scientific (BSX) currently holds an equity stake of roughly 27%.
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows
by Zacks Equity Research
The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.
Quest Diagnostics (DGX) Base Business Rebounds Amid Price Woe
by Zacks Equity Research
Contributions from acquisitions and Professional Lab Services relationships accelerate base business growth for Quest Diagnostics (DGX).
CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.